Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:
“Two FDA approvals in one day.
Capivasertib combination in prostate cancer.
Belzutifan and pembrolizumab combination in kidney cancer.
We take great pride in being involved as Ankara Üniversitesi in both studies.
Today’s biggest thanks go to our patients and their loved ones. For believing in science, trusting it, and walking this path with us. Because science advances with their courage.”
Other srticles featuring Yüksel Ürün on OncoDaily.
